⌘K

21:52:51·70d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Citius Oncology Inc.

ByQuantisnow·Wall Street's wire, on your screen.

CTOR· Citius Oncology Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

CTOR
Citius Oncology Inc.
Health Care

Recent analyst ratings

Sep 23UpdateMaxim Group$6.00
Nov 27UpdateMaxim Group$3.00

Related

SEC12h
Citius Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
SEC28d
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR35d
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
SEC49d
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR49d
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
SEC55d
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
PR55d
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
SEC57d
SEC Form EFFECT filed by Citius Oncology Inc.